CLINICAL TRIALS PROFILE FOR NEOMYCIN SULFATE AND DEXAMETHASONE SODIUM PHOSPHATE

All Clinical Trials for NEOMYCIN SULFATE AND DEXAMETHASONE SODIUM PHOSPHATE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT05999955 ↗	Safety and Efficacy of DSM 32444 Postbiotic in the Treatment of Acute Rhinosinusitis	Completed	Vietstar Biomedical Research	N/A	2022-12-29	Rhinitis is a type of upper respiratory infection with a common nasal pathology especially in Southeast Asia, which is characterized by the presence of one or more of the following symptoms: itchy nose, sneezing, runny nose, and nasal congestion. Other symptoms occasionally experienced include headache, excessive pain reaction, cough, fever. Rhinitis can be idiopathic or due to a variety of causes, including allergens, medications, endocrine/metabolic, infectious, inflammatory, and abnormal nasal structures. The treatment of acute rhinosinusitis and allergic rhinitis in hospitals is currently carried out according to the general professional guidance of the Vietnam Ministry of Health. Most patients are prescribed corticosteroids, antihistamines, and antibiotics for immediate decongestion and anti-inflammatory effects. Current concerns about antimicrobial resistance (AMR) as well as side effects of corticosteroids and antihistamines have led to an urgent need for a naturebased next generation therapeutic approach that is safe, effective and helps in addressing the issues of AMR. The goal of this interventional study is to evaluate the safety and efficacy of postbiotic nasal spray using inert bioparticles of Bacillus subtilis DSM32444 in treatment of acute rhinosinusitis; and to compare the efficacy against Neomycin/Dexamethasone//Xylometazoline administered as a nasal spray as an adjunct to Amoxicillin/Clavulanate standard treatment in patients with acute rhinosinusitis. Patients with acute rhinosinusitis who give consent to participate in the study will be randomly assigned in a 1:1 ratio to one of two groups using postbiotic of Bacillus subtilis DSM32444 nasal spray ("Sperovid") or Neomycin/ Dexamethasone nasal spray for a period of 10 days. Investigators will compare whether the nasal spray using postbiotic Bacillus subtilis DSM32444 has similar efficacy as compared to Neomycin/Dexamethasone/Xylometazoline nasal spray as an adjuvant therapy along with the standard Amoxicillin/Clavulanate regimen in patients with acute rhinosinusitis based on time to improvement of rhinosinusitis symptoms.
NCT05999955 ↗	Safety and Efficacy of DSM 32444 Postbiotic in the Treatment of Acute Rhinosinusitis	Completed	Huro Biotech Joint Stock Company	N/A	2022-12-29	Rhinitis is a type of upper respiratory infection with a common nasal pathology especially in Southeast Asia, which is characterized by the presence of one or more of the following symptoms: itchy nose, sneezing, runny nose, and nasal congestion. Other symptoms occasionally experienced include headache, excessive pain reaction, cough, fever. Rhinitis can be idiopathic or due to a variety of causes, including allergens, medications, endocrine/metabolic, infectious, inflammatory, and abnormal nasal structures. The treatment of acute rhinosinusitis and allergic rhinitis in hospitals is currently carried out according to the general professional guidance of the Vietnam Ministry of Health. Most patients are prescribed corticosteroids, antihistamines, and antibiotics for immediate decongestion and anti-inflammatory effects. Current concerns about antimicrobial resistance (AMR) as well as side effects of corticosteroids and antihistamines have led to an urgent need for a naturebased next generation therapeutic approach that is safe, effective and helps in addressing the issues of AMR. The goal of this interventional study is to evaluate the safety and efficacy of postbiotic nasal spray using inert bioparticles of Bacillus subtilis DSM32444 in treatment of acute rhinosinusitis; and to compare the efficacy against Neomycin/Dexamethasone//Xylometazoline administered as a nasal spray as an adjunct to Amoxicillin/Clavulanate standard treatment in patients with acute rhinosinusitis. Patients with acute rhinosinusitis who give consent to participate in the study will be randomly assigned in a 1:1 ratio to one of two groups using postbiotic of Bacillus subtilis DSM32444 nasal spray ("Sperovid") or Neomycin/ Dexamethasone nasal spray for a period of 10 days. Investigators will compare whether the nasal spray using postbiotic Bacillus subtilis DSM32444 has similar efficacy as compared to Neomycin/Dexamethasone/Xylometazoline nasal spray as an adjuvant therapy along with the standard Amoxicillin/Clavulanate regimen in patients with acute rhinosinusitis based on time to improvement of rhinosinusitis symptoms.

Clinical Trial Conditions for NEOMYCIN SULFATE AND DEXAMETHASONE SODIUM PHOSPHATE

Condition Name

Condition Name for NEOMYCIN SULFATE AND DEXAMETHASONE SODIUM PHOSPHATE
Intervention	Trials
Rhinitis	1
Rhinosinusitis	1

Condition MeSH

Condition MeSH for NEOMYCIN SULFATE AND DEXAMETHASONE SODIUM PHOSPHATE
Intervention	Trials
Sinusitis	1
Rhinosinusitis	1
Rhinitis	1

Clinical Trial Locations for NEOMYCIN SULFATE AND DEXAMETHASONE SODIUM PHOSPHATE

Trials by Country

Trials by Country for NEOMYCIN SULFATE AND DEXAMETHASONE SODIUM PHOSPHATE
Location	Trials
Vietnam	1

Clinical Trial Progress for NEOMYCIN SULFATE AND DEXAMETHASONE SODIUM PHOSPHATE

Clinical Trial Phase

Clinical Trial Phase for NEOMYCIN SULFATE AND DEXAMETHASONE SODIUM PHOSPHATE
Clinical Trial Phase	Trials
N/A	1

Clinical Trial Status

Clinical Trial Status for NEOMYCIN SULFATE AND DEXAMETHASONE SODIUM PHOSPHATE
Clinical Trial Phase	Trials
Completed	1

Clinical Trial Sponsors for NEOMYCIN SULFATE AND DEXAMETHASONE SODIUM PHOSPHATE

Sponsor Name

Sponsor Name for NEOMYCIN SULFATE AND DEXAMETHASONE SODIUM PHOSPHATE
Sponsor	Trials
Vietstar Biomedical Research	1
Huro Biotech Joint Stock Company	1

Sponsor Type

Sponsor Type for NEOMYCIN SULFATE AND DEXAMETHASONE SODIUM PHOSPHATE
Sponsor	Trials
Industry	2

Last updated: May 4, 2026

NEOMYCIN SULFATE AND DEXAMETHASONE SODIUM PHOSPHATE: Clinical-Readout, Market Structure, and Forecast-Relevant Demand Drivers

Summary: Public clinical-trial visibility for “neomycin sulfate and dexamethasone sodium phosphate” is limited and product-specific, with the compound typically marketed as an ophthalmic or otic combination rather than a stand-alone late-stage development program. Commercial projections therefore hinge on (1) shelf-stable branded/authorized generics in established ocular/ear indications, (2) regulatory life-cycle through brand-to-generic conversion and label maintenance, (3) substitution dynamics versus newer anti-infective and anti-inflammatory regimens, and (4) litigation and regulatory exclusivity around specific branded formulations. Current publicly accessible sources do not support a complete, up-to-date cross-sponsor “clinical trials update” with reliable phase status and readouts for the exact combination across all geographies.

Bottom line: Use this drug as a category-and-label-driven demand asset, not as a clinical pipeline-led bet, unless a specific formulation or NDA/ANDA shows active late-stage enrollment or new indication filings in your target region.

---

What is this combination and where is it used commercially?

Neomycin sulfate and dexamethasone sodium phosphate is a fixed-dose antibiotic-steroid combination used to treat inflammatory or infectious conditions where both antimicrobial activity and corticosteroid suppression are intended.

Typical use patterns in practice and labeling (by product form):

• Ophthalmic: treatment of corticosteroid-responsive inflammatory conditions of the eye where bacterial infection or risk of bacterial infection exists.
• Otic (ear): treatment of inflammatory conditions of the external ear canal with suspected or confirmed bacterial involvement, where a steroid is indicated to reduce inflammation.

Market implication: Demand clusters around established, low-to-moderate unit therapies that tend to be:

• Chronic-cycle purchases (acute episodes driving repeat prescribing),
• Formulation- and brand-dependent (dropper ease, concentration, vehicle tolerability),
• Price-tier sensitive after generic entry.

---

Is there a current, verifiable clinical trial pipeline update for this exact combination?

A complete clinical update requires verifiable trial records (study sponsor, NCT identifier, phase, enrollment status, sites/region, and readout date) tied to the exact combination and dosage form. In the publicly indexed sources available for this task, there is no sufficiently complete, reliable set of up-to-date, combination-specific late-stage results that can be compiled into a single “trial update” with the required precision.

What you can still use operationally:

• Treat the combination as a mature-ingredient therapy where most measurable clinical activity in public registries tends to be either:
  • formulation bioequivalence work for generics (not a phase-style “readout”), or
  • older historical efficacy safety comparisons, which do not provide current pipeline momentum for valuation.

Clinical action for business planning (what matters despite limited registry visibility):

• If your investment thesis depends on growth from new evidence, it should be tied to:
  • a specific brand NDA/BLA label expansion,
  • a region-specific supplemental approval,
  • or a new dosage form with a dedicated regulatory path.

Without these anchors, clinical readouts do not provide a dependable basis for forward revenue projection.

---

How does the market structure typically look for this combination?

What is the competitive landscape: brands vs generics vs substitution?

This combination normally sits in a market segment characterized by:

• Branded originators and multiple ANDA generics for ophthalmic/otic presentations, and
• Substitution pressure from:
  • single-agent anti-infectives paired with separate anti-inflammatory products,
  • newer fluoroquinolone-based antibiotic combinations (where label and prescriber habits allow),
  • steroid-only regimens in cases where clinicians determine infection risk is low.

Where does pricing power come from?

Pricing power usually depends on:

• market share durability post-generic entry,
• brand-specific differentiation (formulation, device, packaging, patient-use factors),
• channel dynamics (hospital formularies vs community).

What are the operational risks?

For antibiotic-steroid combinations, the main pressure points are:

• safety-driven prescribing (aminoglycoside-associated hypersensitivity concerns),
• steriod stewardship (avoidance when infection control is uncertain),
• and label compliance (duration limits and contraindications).

---

What demand drivers support a base-case forecast?

1) Acute-indication incidence and clinician behavior

Demand tracks acute episode volume in the treated conditions. Forecast models typically scale with:

• outpatient visit volume (ophthalmic and otic),
• seasonal variation for ear conditions,
• and relative prescribing behavior across competing regimens.

2) Switch velocity after generic entry

Assuming generics exist in the target geography, the forecast needs a generic switch curve:

• initial erosion in price and share after entry,
• plateau at generic-competitor saturation,
• periodic share shifts tied to pricing and procurement.

3) Formulation/device effects

For ophthalmic drops and otic solutions, “ease of use” and tolerability influence:

• repeat prescribing,
• substitution by pharmacists,
• and adherence-related outcomes (indirectly supporting continuation).

4) Regulatory life-cycle events

Forecast-relevant events include:

• exclusivity expirations for branded formulations,
• patent settlements (if they result in early or delayed generic entry),
• label updates (safety changes that could alter patient segment).

---

What forecast projection can be made from publicly supportable data?

A defensible numeric market forecast cannot be produced from the information available in this task without a specific dataset: e.g., country-by-country sales by NDC, shipment data, IMS/IQVIA extracts, or insurer claims. This request also asks for clinical-trial updates, which are not verifiably complete for the exact combination.

Actionable projection framework (non-numeric, decision-grade):

• Base-case: mature product class with modest growth aligned to volume plus mild price compression if generics are dominant.
• Bear-case: faster substitution toward newer single-agent anti-infectives or antibiotic-only pathways; stronger steroid-sparing stewardship; adverse safety scrutiny affecting restricted-use volume.
• Bull-case: sustained brand share due to procurement preference or payer placement; fewer competitive entries; favorable label maintenance with minimal safety-driven restrictions.

---

What should investors and R&D leaders monitor (the specific signals that change the forecast)?

Key signals

• Regulatory submissions and approvals tied to a named formulation (NDA/ANDA, supplement type, and label language change).
• Patent status updates for the branded formulation in major markets.
• New RCTs or comparative trials that use the exact combination in the same dosage form and target population, with published endpoints and readout dates.
• Formulary and payer placement changes in your target segments (ophthalmology clinics, ENT practices, hospital outpatient).

Operational checklists by category

• Ophthalmic: track anti-infective regimen competition, steroid duration guidance, and any updated warnings.
• Otic: track antibiotic-steroid substitution and the use frequency of alternative ear drops after genericization.

---

Key Takeaways

• Neomycin sulfate and dexamethasone sodium phosphate is a mature antibiotic-steroid combination used in ophthalmic and otic indications, typically supplied via branded and generic versions.
• A complete, up-to-date clinical trials readout for the exact combination is not sufficiently verifiable from the available public sources in this task.
• Market outlook should be modeled primarily from label and formulation-driven demand, generic switch velocity, substitution pressure from alternative regimens, and regulatory/patent life-cycle events.
• Forecast confidence improves when anchored to a specific branded formulation’s regulatory and patent status in your target geographies.

---

FAQs

1) Is there active Phase 3 evidence for neomycin sulfate and dexamethasone sodium phosphate?
No sufficiently complete, combination-specific Phase 3 readout set is verifiably present in the available public information in this task.

2) What drives sales for this combination more: clinical innovation or volume?
Volume and prescribing behavior in acute ocular/ear indications typically dominate for mature combination products, with limited pipeline-led upside unless a label or formulation expansion is underway.

3) How does generic entry typically affect pricing and market share?
It usually compresses price and drives a share shift toward lower-cost producers, with a plateau once multiple generics saturate purchasing channels.

4) What substitution risks matter most?
Clinically, antibiotic-only regimens and newer anti-infective strategies can reduce reliance on antibiotic-steroid combinations when prescribers assess infection risk and steroid need differently.

5) What signals would indicate a bull-case forecast?
Favorable label maintenance without added restrictions, durable brand procurement, delayed competitive entry, or a clearly evidenced new regulatory expansion for a specific formulation.

---

References (APA)

[1] U.S. National Library of Medicine. (n.d.). ClinicalTrials.gov. https://clinicaltrials.gov/
[2] U.S. Food and Drug Administration. (n.d.). Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/